<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01698203</url>
  </required_header>
  <id_info>
    <org_study_id>5277</org_study_id>
    <nct_id>NCT01698203</nct_id>
  </id_info>
  <brief_title>Continuous Wound Catheter Analgesia Associated With Intravenous Morphine PCA After Thoracotomy</brief_title>
  <official_title>Postoperative Analgesia After Thoracotomy Without Thoracic Epidural Analgesia: Continuous Wound Catheter Analgesia Associated With Intravenous Morphine Patient-Controlled-Analgesia (PCA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: Epidural analgesia is the gold standard for post-thoracotomy pain relief but is&#xD;
      contraindicated in certain patients. An alternative is continuous wound catheter analgesia.&#xD;
      We will investigate whether ropivacaine, administered through a wound catheter placed by the&#xD;
      surgeon, will reduce postoperative pain. Methods: In a randomized double-blind study, adult&#xD;
      patients with a wound catheter placed by the thoracic surgeon after thoracotomy will be&#xD;
      randomly assigned to receive through this catheter, either a 0.1 mL/kg bolus of 0.75%&#xD;
      ropivacaine, followed by a continuous infusion of 0.2% ropivacaine at 10 mL/h for 48 h, or&#xD;
      saline at the same scheme of administration. Patients will also benefit from&#xD;
      patient-controlled analgesia with intravenous morphine (bolus 1 mg, lockout time 7 min),&#xD;
      paracetamol, and nefopam. The primary endpoint will be total morphine consumption. Secondary&#xD;
      endpoints will be pain intensity on a visual analog scale at rest and on coughing and side&#xD;
      effects during the first 48 postoperative hours. Surgeons, anesthesiologists, and all the&#xD;
      nurses and caring staff involved in this study will be blinded. Solutions of saline and&#xD;
      ropivacaine will be prepared identically by the central pharmacy, without any possible&#xD;
      identification of the product.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 14, 2012</start_date>
  <completion_date type="Actual">October 11, 2018</completion_date>
  <primary_completion_date type="Actual">October 14, 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total intravenous morphine consumption (mg)</measure>
    <time_frame>the first 48 hours after surgery</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Pain</condition>
  <condition>Thoracotomy</condition>
  <arm_group>
    <arm_group_label>ropivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ropivacaine 0.75% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)</intervention_name>
    <description>The group ropivacaine, an initial bolus of 0.75% ropivacaine at a volume of 0.1 ml / kg is first administered to the patient directly on the catheter.</description>
    <arm_group_label>ropivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>In the placebo group, an initial bolus of saline 9 ‰ to a volume of 0.1 ml / kg will first be administered to the patient directly to the catheter. The patient will then continuous administration of saline 9 ‰ during the first 48 postoperative hours, using a diffuser extensible elastomeric ™ Easypump a volume of 400 mL to 460 mL filled of this solution, a flow rate of 9.53 ml / hour.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ropivacaine 0.2% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)</intervention_name>
    <description>The patient will then ongoing administration of ropivacaine 0.2% during the first 48 postoperative hours, using a diffuser extensible elastomeric ™ Easypump a volume of 400 mL to 460 mL filled (B Braun) of this solution, a flow rate of 9.53 ml / hour</description>
    <arm_group_label>ropivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients scheduled for thoracotomy who presented with contraindications to TEA.&#xD;
&#xD;
        Contraindications to TEA are :&#xD;
&#xD;
          -  Patient's refusal after informations about advantages and risks of the technique&#xD;
&#xD;
          -  Anti platelets treatment that can't be discontinued&#xD;
&#xD;
          -  Anticoagulants at a curative dosage&#xD;
&#xD;
          -  haemostasis and/or coagulation disorders: thrombopenia &lt; 100.000/mm3, ACT &gt; 1,5 /&#xD;
             control, PTT &lt; 75%&#xD;
&#xD;
          -  Systemic or local infection of the puncture point&#xD;
&#xD;
          -  2 and 3 grade atrio-ventricular heart block without pacing&#xD;
&#xD;
          -  Severe aortic valve stenosis&#xD;
&#xD;
          -  Kyphoscoliosis&#xD;
&#xD;
          -  certain neurological disorders&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient's refusal to participate in the study&#xD;
&#xD;
          -  Psychiatric disorder (impossibility to collect the informed consent)&#xD;
&#xD;
          -  Patient under juridical protection&#xD;
&#xD;
          -  On going an other study&#xD;
&#xD;
          -  Pregnancy, breastfeeding&#xD;
&#xD;
          -  Non balanced epilepsy&#xD;
&#xD;
          -  3 grade auriculo-ventricular heart block without pacing&#xD;
&#xD;
          -  Severe hepatocellular insufficiency&#xD;
&#xD;
          -  Anti arrhythmic treatment : class III of the Vaughan William's classification&#xD;
&#xD;
          -  Skin infection of the puncture point&#xD;
&#xD;
          -  Allergy to aminoamides local anaesthetic&#xD;
&#xD;
          -  Surgical difficulties to insert paravertebral catheter&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Helms, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Civil - NHC Département d'Anesthésiologie</name>
      <address>
        <city>STRASBOURG Cedex</city>
        <state>Alsace</state>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 28, 2012</study_first_submitted>
  <study_first_submitted_qc>October 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2012</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

